- Home
- EML vs IKT Comparison
EML vs IKT Comparison
Compare EML & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EML
- IKT
- Stock Information
- Founded
- EML 1858
- IKT 2008
- Country
- EML United States
- IKT United States
- Employees
- EML N/A
- IKT N/A
- Industry
- EML Industrial Machinery/Components
- IKT Biotechnology: Pharmaceutical Preparations
- Sector
- EML Consumer Discretionary
- IKT Health Care
- Exchange
- EML Nasdaq
- IKT Nasdaq
- Market Cap
- EML 175.5M
- IKT 167.2M
- IPO Year
- EML N/A
- IKT 2020
- Fundamental
- Price
- EML $27.05
- IKT $2.23
- Analyst Decision
- EML
- IKT Buy
- Analyst Count
- EML 0
- IKT 2
- Target Price
- EML N/A
- IKT $8.00
- AVG Volume (30 Days)
- EML 7.8K
- IKT 168.5K
- Earning Date
- EML 03-11-2025
- IKT 03-26-2025
- Dividend Yield
- EML 1.64%
- IKT N/A
- EPS Growth
- EML N/A
- IKT N/A
- EPS
- EML N/A
- IKT N/A
- Revenue
- EML $272,751,967.00
- IKT $1.00
- Revenue This Year
- EML N/A
- IKT N/A
- Revenue Next Year
- EML N/A
- IKT N/A
- P/E Ratio
- EML $12.95
- IKT N/A
- Revenue Growth
- EML 5.37
- IKT N/A
- 52 Week Low
- EML $23.15
- IKT $1.12
- 52 Week High
- EML $35.78
- IKT $4.20
- Technical
- Relative Strength Index (RSI)
- EML 46.48
- IKT 45.81
- Support Level
- EML $26.25
- IKT $1.91
- Resistance Level
- EML $28.26
- IKT $2.22
- Average True Range (ATR)
- EML 0.90
- IKT 0.27
- MACD
- EML -0.06
- IKT -0.02
- Stochastic Oscillator
- EML 28.99
- IKT 22.70
About EML Eastern Company (The)
The Eastern Co manages industrial businesses that design, manufacture, and sell engineered solutions to industrial markets. The company manages the financial, operational, and strategic performance of its businesses to increase cash generation, operating earnings, and long-term shareholder value. It operates in the United States and Other Countries and generates the majority of its revenue from the United States.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.